Antioxidant activity of maslinic acid, a triterpene derivative obtained from Olea europaea.

Planta Medica (Impact Factor: 2.34). 06/2003; 69(5):472-4. DOI: 10.1055/s-2003-39698
Source: PubMed

ABSTRACT We investigated the effect of maslinic acid (a triterpene derivative obtained from olive pomace), on the susceptibility of plasma or hepatocyte membranes to lipid peroxidation (LPO), induced respectively by the hydroxyl radical (OH*) generated by Fe2+/H2O2 ex vivo and by the system Fe3+/ascorbate in vitro; moreover, three groups of animals used in the plasma study were pretreated with CCl4 (to generate CCl3-*). Endogenous plasma lipoperoxide levels and susceptibility to LPO were decreased in rats treated with maslinic acid, after exposure to OH* by Fe2+/H2O2 (Fenton reaction). Co-incubation with maslinic acid prevented hepatocyte membrane LPO as shown by the reduction of TBARS. In conclusion, maslinic acid may offer some advantages in the resistance of oxidative stress in the animals.


Available from: Andres Parra, Apr 07, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pentacyclic triterpenes are natural substances, synthesized and present in variable amounts in a large number of terrestrial and aquatic plants, acting as antioxidants and antimicrobials, and also as poisons, antibiotics, protease inhibitors, and so on. From the organic chemical point of view, they are compounds derived from isoprene. These are compounds consisting of 30 carbons presenting different substituents which facilitate chemical identification and also confer different physicochemical and molecular properties. During the last ten years, most of them have been described as having a huge variety of interesting and significant biological properties, such as analgesic, anti-allodynic, anti-diabetic, anti-oxidant, anti-parasitic, anti-microbial, anti-viral, anti-atherogenic, anti-inflammatory, anti-proliferative, anti-tumour, growth-stimulating activities as well as cardio- and neuro-protective activity. However, special attention has been focused on the study of their anti-tumour capacity, focused fundamentally on the various molecular mechanisms involved in the induction of programmed cell death and the inhibition of metastatic activity, in accordance with different types of cancers. Researchers have also focused on the role that different RNA molecules play in the anti-tumour activity of the major triterpenes studied. The purpose of this paper is to review the recent advances described for the main representatives of this group of compounds, such as betulinic (BA), ursolic (UA), oleanolic (OA) and maslinic (MA) acids and some of their derivatives, and on their anti-tumourigenic role, with special emphasis on cell apoptosis and angiogenesis.
    Current Organic Chemistry 05/2015; 19(10):919-947. DOI:10.2174/1385272819666150119225952 · 2.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The activity of the methanol extract of the whole plant of Kalanchoe crenata (MEKC) was studied for the treatment of diabetes-induced nephropathy in rats.Methods: Five-day old Wistar rats received a single intraperitoneal streptozotocin injection (90 ìg/kg body weight) to induce diabetes. Kidney disease onset in the rats was observed six weeks after diabetes induction. The rats were orally administered MEKC (0, 50 and 68 mg/kg) or glibenclamide (5 mg/kg), once daily for 6 weeks. Blood and urine glucose, proteins, lipids, creatinine, malondialdehyde (MDA), superoxide dismutase (SOD) and catalase (CAT) were then evaluated.Results: After 6 weeks of treatment, 50 and 68 mg/kg MEKC, and glibenclamide significantly (p < 0.01) decreased glycaemia (-35, -44 and -39 %), glycosuria (-38, -47 and -61 %) and proteinuria (-82, -80 and-72 %) in diabetes-nephropathic rats. The extract (68 mg/kg) decreased MDA by up to -44 % (blood), -35 % (liver) and -34 % (kidney); increased SOD up to 257 % (blood), 116 % (liver) and 118 % (kidney); and CAT by up to 176 % (blood), 78 % (liver) and 96 % (kidney) in the rats, compared with nephropathic control. The extract (50 and 68 mg/kg, respectively) lowered (p < 0.01) total cholesterolemia (-24 and - 27 %), blood triglycerides (-55 and -54 %), blood LDL cholesterol (-48 and -59 %), but increased blood HDL cholesterol (71 and 58 %). Overall, atherogenic index was decreased by 31 %.Conclusion: The results indicate that MEKC holds promise for the development of a standardized phytomedicine for diabetes mellitus and kidney disease treatment.
    02/2013; 11(5). DOI:10.4314/tjpr.v11i5.10
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim of the Review. To grasp the fragmented information available on the botany, traditional uses, phytochemistry, pharmacology, and toxicology of Olea europaea to explore its therapeutic potential and future research opportunities. Material and Methods. All the available information on O. europaea was collected via electronic search (using Pubmed, Scirus, Google Scholar, and Web of Science) and a library search. Results. Ethnomedical uses of O. europaea are recorded throughout the world where it has been used to treat various ailments. Phytochemical research had led to the isolation of flavonoids, secoiridoids, iridoids, flavanones, biophenols, triterpenes, benzoic acid derivatives, isochromans, and other classes of secondary metabolites from O. europaea. The plant materials and isolated components have shown a wide spectrum of in vitro and in vivo pharmacological activities like antidiabetic, anticonvulsant, antioxidant, anti-inflammatory, immunomodulatory, analgesic, antimicrobial, antiviral, antihypertensive, anticancer, antihyperglycemic, antinociceptive, gastroprotective, and wound healing activities. Conclusions. O. europaea emerged as a good source of traditional medicine for the treatment of various ailments. The outcomes of phytochemical and pharmacological studies reported in this review will further expand its existing therapeutic potential and provide a convincing support to its future clinical use in modern medicine.
    Evidence-based Complementary and Alternative Medicine 01/2015; 2015:541591. DOI:10.1155/2015/541591 · 2.18 Impact Factor